Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Hanmi Pharmaceutical y Beijing Hanmi avanzan en los ensayos clínicos del BH3120 como inmunoterapia

      Hanmi Pharmaceutical Logo

      News provided by

      Hanmi Pharmaceutical

      Nov 25, 2024, 07:19 ET

      Share this article

      Share this article


      - Hanmi Pharmaceutical y Beijing Hanmi avanzan en los ensayos clínicos del BH3120, desarrollado conjuntamente, como inmunoterapia contra el cáncer de próxima generación

      • Hanmi presenta un póster de ensayo en curso sobre BH3120 en la Sociedad de Inmunoterapia del Cáncer (SITC) en Estados Unidos
      • El ensayo de fase 1 avanza sin problemas y no se observa toxicidad limitante de la dosis
      • Ensayo de fase 1 que evalúa la combinación de BH3120 y la terapia anti-PD-1 de MSD, KEYTRUDA® (pembrolizumab), en marcha

      SEÚL, Corea del sur, 25 de noviembre de 2024 /PRNewswire/ -- El último avance en el ensayo clínico de BH3120, una inmunoterapia innovadora desarrollada conjuntamente por Hanmi Pharmaceutical y Beijing Hanmi Pharmaceutical, se presentó recientemente en una importante conferencia académica mundial, atrayendo una atención significativa en el campo de la inmunoterapia.

      El 25 de noviembre, Hanmi anunció que presentó la investigación y el progreso clínico de BH3120 en una sesión de carteles en la conferencia de la Sociedad de Inmunoterapia del Cáncer (SITC), celebrada en Houston, Estados Unidos, del 6 al 10 de noviembre.

      BH3120 es un nuevo fármaco contra el cáncer basado en la plataforma de anticuerpos duales patentada por Hanmi, "Pentambody". Esta tecnología permite que un solo anticuerpo se una simultáneamente a dos dianas distintas, lo que permite una acción anticancerígena dirigida al atacar específicamente a las células cancerosas mientras se activan las células inmunes para mejorar los efectos de la inmunoterapia.

      BH3120 está diseñado para atacar a PD-L1 en las células cancerosas y a 4-1BB en las células inmunes, actuando así como un "puente" que facilita el reconocimiento y la eliminación de las células tumorales por parte de las células inmunes.

      Mientras que otros anticuerpos candidatos dirigidos contra el 4-1BB han enfrentado desafíos en cuanto a eficacia o seguridad anticancerígena, los estudios preclínicos de BH3120 revelan una sólida eficacia anticancerígena junto con una disociación única de la actividad inmunitaria entre el microambiente tumoral (TME) y los tejidos normales. Este mecanismo distintivo resalta el potencial de BH3120 como un gran avance en el desarrollo de una terapia anticancerígena efectiva y más segura.

      Durante la presentación de SITC, Hanmi describió los antecedentes, el diseño y el progreso clínico del BH3120. Actualmente, se está llevando a cabo un ensayo clínico de fase 1 global en Corea del Sur y Estados Unidos, que evalúa la seguridad y la tolerabilidad del BH3120 como monoterapia en pacientes con tumores sólidos avanzados o metastásicos.

      El ensayo clínico de fase 1 ha progresado sin problemas a través de la cohorte 3 (1 mg/kg) de la fase de aumento de dosis, sin que se hayan observado hasta la fecha toxicidades limitantes de la dosis (DLT) ni reacciones adversas a medicamentos de grado 3 o superior.

      El doctor Dong-wan Kim, director del Centro de Ensayos Clínicos del Hospital Universitario Nacional de Seúl (Departamento de Hemato-Oncología) e investigador principal del ensayo clínico de fase 1 de BH3120, comentó: "El ensayo clínico de fase 1 de BH3120 es un paso fundamental para verificar el potencial de esta inmunoterapia de próxima generación. Somos optimistas sobre la posibilidad de lograr resultados positivos". Añadió: "Esperamos que futuras investigaciones establezcan que BH3120 es una opción de tratamiento eficaz y segura para varios tipos de cáncer, reduciendo los efectos secundarios que suelen asociarse a las inmunoterapias actuales".

      Paralelamente, Hanmi también está llevando a cabo un ensayo de fase 1 para evaluar la seguridad y eficacia de BH3120 en combinación con la terapia anti-PD-1 de MSD (Merck & Co., Inc., Rahway, NJ, Estados Unidos), KEYTRUDA® (pembrolizumab) en pacientes con tumores sólidos avanzados o metastásicos.

      En septiembre, Hanmi obtuvo la aprobación tanto del Ministerio de Seguridad Alimentaria y Farmacéutica de Corea como de la Administración de Alimentos y Medicamentos de Estados Unidos (FDA) para modificar el plan de ensayo de Fase 1 a fin de evaluar BH3120 en combinación con KEYTRUDA. Se espera que el desarrollo clínico a gran escala comience a principios del próximo año. Hanmi actuará como patrocinador principal y llevará a cabo el ensayo clínico, mientras que MSD suministrará KEYTRUDA para el ensayo.

      Young Su Noh, director del equipo clínico de oncología de Hanmi, destacó: "El ensayo BH3120 representa un hito, ya que es el primer proyecto de investigación clínica global de Hanmi que utiliza nuestra plataforma patentada de anticuerpos duales Pentambody en inmunooncología, un campo a la vanguardia de la innovación en el tratamiento del cáncer". Continuó: "Estamos comprometidos con el avance de una inmunoterapia de próxima generación que supere las limitaciones de los tratamientos existentes y mejore la eficacia terapéutica".

      KEYTRUDA® es una marca registrada de Merck Sharp & Dohme LLC, una subsidiaria de Merck & Co., Inc., Rahway, NJ, Estados Unidos.

      • Información de contacto:
        Sitios web oficiales: www.hanmipharm.com

        [email protected], +08-2-410-0467

      Logo - https://mma.prnewswire.com/media/2034330/Hanmi_Pharmaceutical_Logo.jpg

      Modal title

      Also from this source

      Hanmi Secures Export Deal with Mexican Partner Sanfer for GLP-1 Obesity Drug and More

      Hanmi Secures Export Deal with Mexican Partner Sanfer for GLP-1 Obesity Drug and More

      Hanmi is accelerating its global market entry with efpeglenatide, Korea's first domestically developed GLP-1 class obesity and metabolic disease...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Pharmaceuticals

      Pharmaceuticals

      Clinical Trials & Medical Discoveries

      Clinical Trials & Medical Discoveries

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.